* ONCODESIGN *
1995 - Rhône-Alpes
Dijon
www.oncodesign.fr Contract, Research
(also, Discovery, Therapies)
Key words: In-vivo screening, Nude-rat, Cancer, Drug resistance, Translational research, Neurology
Mission: to provide third parties with preclinical evaluation of novel anticancer therapeutics and to identify and validate molecular targets involved in cancer pathologies
Clients: Pharmaceutical industry
contact@oncodesign.com
Age: 17 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Personal venture |
Managing Dir.-CEO: Genne (Philippe) [co-founder, born 1961, Ph.D.]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev: Ewing (Jonathan)
Financers (Hist.): CDC, Avenir Entreprise Gestion, Banque de Vizille | Turnover (M€) : 3.8 (2009), 4.69 (2008), 5.5 (2007)
Total funding (M€) : n.a.
Last funding (M€) : 3.0
Focus : Studies
Position : Subcontractor
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2010 .06 | Licensing-in of macrocyclic chemistry technology from Janssen | LICIN | [15 years] |
| 2009 .08 | Financing (no interest loan) : 10.0 M€, by OSEO Innovation, for oncology biomarker program IMAkinib (with Guerbet and Ariana Pharmaceuticals) | DEBT | [14 years] |
| 2008 .06 | Round-financing : 3.0 M€, by Banque de Vizille, Avenir Entreprise Gestion, in order to invest in USA and neurology | RFIN | [13 years] |
| 2008 .03 | Launch of Pharm'Image platform, a medical imagery pole in Dijon, with local partners (completion planned for 2010) | MKTG | [13 years] |
| 2007 .07 | Set-up of offices in Montréal, Canada | ORGC | [12 years] |
| 1998 .07 | Seed financing : 0.75 M€, by Ideb, Banque Populaire Création | SFIN | [3 years] |
| 1995 .01 | Company founded by Philippe Genne and Eric Solary (today Inserm), both scientists (Lab. Onco-hematology, Dijon University) | ORGF | [0 year] | Actualisation / Updating: 9-May-2011 |
|
